A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

Exclusion Criteria

• •Ocular:
• •1. Use of any of the following treatments or anticipated use of any of the following treatments to the study eye:
• •1. Any intravitreal treatment within 4 weeks prior to Baseline (Visit 1).
• •2. Intravitreal or periocular corticosteroid, within 90 days prior to Visit 1 (Day 1) and throughout the study.
• •3. Fluocinolone acetonide intravitreal implant, within 12 months prior to Visit 1 (Day 1) and throughout the study.
• •4. Visudyne® photodynamic therapy, within 90 days prior to Visit 1 (Day 1) and throughout the study.
• •2. Uncontrolled or advanced glaucoma, evidenced by an intraocular pressure of \> 21 mmHg or cup/disc ratio \> 0.8 while on medical therapy, or chronic hypotony (\< 6 mmHg) in the study eye.
• •3. Evidence of any other ocular disease other than wet age-related macular degeneration in the study eye that may confound the outcome of the study
• •4. History of vitrectomy in the study eye.
• •5. Need for ocular surgery in the study eye during the course of the study.
• •6. YAG laser capsulotomy within 30 days prior to Visit 1 (Day 1) in the study eye.
• •7. Intraocular surgery, including lens removal or laser, within 90 days prior to Visit 1 (Day 1) in the study eye.